Epidemiology of Fluoroquinolone Resistance in Human Commensal Flora in Patients Hospitalised in Medical Wards

This study has been completed.
Sponsor:
Information provided by:
Association Pour le Recherche en Infectiologie et en Médecine Interne
ClinicalTrials.gov Identifier:
NCT00520715
First received: July 11, 2007
Last updated: December 28, 2007
Last verified: December 2007
  Purpose

Emergence of bacterial resistance to antibiotics, which is a major public health issue, appears to involve predominantly commensal flora. No data exists concerning risk factors for the carriage of fluoroquinolone resistant bacteria in the flora of hospitalised patients. We will conduct a prospective open study including all unselected patients hospitalised in medical wards of one hospital. Nasal, pharyngeal and rectal swabs will be performed upon admission as well as a review of potential risk factors, after patient's information and acceptance. Resistance testing aiming 3 pathogens (Staphylococcus, Streptococcus and E. coli) will be performed on all specimens, and a case control study will compare risk factors from the resistant and non-resistant groups, for each pathogen. A thousand patients should be included in a year's time. This work could help understand risk factors involved in the carriage of fluoroquinolone resistant pathogens, potentially responsible for invasive infections and inter-patient transmission of resistance. Limiting bacterial resistance and transmission is a goal that can be successfully undertaken only if resistance mechanisms, but also risk factors of acquiring resistant bacteria are better understood.


Condition
Carriage of Fluoroquinolone Resistant Bacteria in Commensal Flora.

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Epidemiology and Risk Factors Study of the Carriage of Fluoroquinolone Resistant Bacteria in the Commensal Flora of Patients Hospitalised in Medical Wards

Further study details as provided by Association Pour le Recherche en Infectiologie et en Médecine Interne:

Enrollment: 640
Study Start Date: June 2007
Study Completion Date: December 2007
Estimated Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all adult patients admitted to the internal medicine, oncology, cardiology and geriatric unit of Beaujon Hospital, Clichy, France.
  • patient agreement

Exclusion Criteria:

  • Age < 18
  • patient refusal or incapable
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00520715

Locations
France
Hôpital Beaujon
Clichy, Ile de France, France, 92110
Sponsors and Collaborators
Association Pour le Recherche en Infectiologie et en Médecine Interne
Investigators
Principal Investigator: Victoire de Lastours, MD
  More Information

No publications provided by Association Pour le Recherche en Infectiologie et en Médecine Interne

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00520715     History of Changes
Other Study ID Numbers: FQ/EPI
Study First Received: July 11, 2007
Last Updated: December 28, 2007
Health Authority: France: Institutional Ethical Committee
France: French Data Protection Authority

Keywords provided by Association Pour le Recherche en Infectiologie et en Médecine Interne:
fluoroquinolone resistance
commensal flora
carriage

Additional relevant MeSH terms:
Fluoroquinolones
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 23, 2014